Angiosarcoma of the scalp: A case report and review of current and novel therapeutic regimens

Dermatologic Surgery

Volumn 35, Issue 4, 2009, Pages 679-684

  Gonzalez, Michele J ^a   Koehler, Matthew M ^a   Satter, Elizabeth K ^a  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; BEVACIZUMAB; CD31 ANTIGEN; CD34 ANTIGEN; DOCETAXEL; DOXORUBICIN; IFOSFAMIDE; IMATINIB; MESNA; PACLITAXEL; TAXANE DERIVATIVE;

ADJUVANT THERAPY; AGED; ANGIOSARCOMA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CASE REPORT; COLORECTAL CARCINOMA; FATIGUE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MALE; METASTASIS; MUCOSA INFLAMMATION; PANCYTOPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PUNCH BIOPSY; SCALP ANGIOSARCOMA; UNSPECIFIED SIDE EFFECT;

AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HEMANGIOSARCOMA; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; RADIOTHERAPY, ADJUVANT; SCALP; SKIN TRANSPLANTATION; SURGICAL FLAPS;

EID: 64349121285     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2009.01116.x     Document Type: Article

References (31)

1. North PE, Hull C, Kincannon J. Vascular neoplasms and neoplastic-like proliferations. In : Bolognia JL, Jorizzo JL, Rapini RP, editors. Dermatology. 1st edn. Mosby 2003. p. 1817 41.
2. Fata F, O'Reilly E, Ilson D, et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 1999 86 : 2034 7.
3. Morgan MB, Swann M, Somach S, et al. Cutaneous angiosarcoma: a case series with prognostic correlation. J Am Acad Dermatol 2004 50 : 867 74.
4. Holden CA, Spittle MF, Jones EW. Angiosarcoma of the face and scalp, prognosis and treatment. Cancer 1987 59 : 1046 57.
5. Pawlik TM, Paulino AF, Mcginn CJ, et al. Cutaneous angiosarcoma of the scalp: a multidisciplinary approach. Cancer 2003 98 : 1716 26.
6. Woodward AH, Ivins JC, Soule EH. Lymphangiosarcoma in chronic lymphedematous extremities. Cancer 1972 30 : 562 72.
7. Nanus DM, Kelson D, Clark DG. Radiation-induced angiosarcoma. Cancer 1987 60 : 777 9.
8. Monroe AT, Feigenberg SJ, Mendenhall NP. Angiosarcoma after breast-conserving therapy. Cancer 2003 97 : 1832 40.
9. Falk H, Thomas LB, Popper H, et al. Hepatic angiosarcoma associated with androgenic-anabolic steroids. Lancet 1979 314 : 1120 3.
10. Mark RJ, Tran LM, Sercarz J, et al. Angiosarcoma of the head and neck: the UCLA experience 1955 through 1990. Arch Otolaryngol Head Neck Surg 1993 119 : 973 8.
11. Mark RJ, Poen JC, Tran LM, et al. Angiosarcoma: a report of 67 patients and review of the literature. Cancer 1996 77 : 2400 6.
12. Fury MG, Antonescu CR, Van Zee KJ, et al. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J 2005 11 : 241 7.
13. Elias AD, Antman KH. Adjuvant chemotherapy for soft tissue sarcoma: an approach in search of an effective regimen. Semin Oncol 1989 16 : 305 11.
14. Morrison WH, Byers RB, Garden AS, et al. Cutaneous angiosarcoma of the head and neck. A therapeutic dilemma. Cancer 1995 76 : 319 27.
15. Abraham JA, Horniceck FJ, Kaufman AM, et al. Treatment and outcome of 82 patients with angiosarcoma. Ann Surg Oncol 2007 14 : 1953 67.
16. Skubitz KM, Haddad PA. Paclitaxel and pegylated-lisosomal doxorubicin are both active in angiosarcoma. Cancer 2005 104 : 361 6.
17. Maddox JC, Evans HL. Angiosarcoma of skin and soft tissue: a study of forty-four cases. Cancer 1981 48 : 1907 21.
18. Mizutani H, Tada-Oikawa S, Hiraku Y, et al. Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide. Life Sci 2005 76 : 1439 53.
19. Bong AB, Bonnekoh B, Schon MP, et al. Treatment of scalp angiosarcoma by controlled perfusion of A. carotis externa with pegylated liposomal doxorubicin and intralesional application of pegylated interferon alfa. J Am Acad Dermatol 2005 52 : S20 3.
20. Belotti D, Vergani V, Drudis T, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996 2 : 1843 9.
21. Nagano T, Yamada Y, Ikeda T, et al. Docetaxel: a therapeutic option in the treatment of cutaneous angiosarcoma. Cancer 2007 110 : 648 51.
22. Kondapalli L, Soltani K, Lacouture ME. The promise of molecular targeted therapies: protein kinase inhibitors in the treatment of cutaneous malignancies. J Am Acad Dermatol 2005 53 : 291 302.
23. Miettinen M, Sarlomo-Rikala M, Lasota J. KIT expression in angiosarcomas and fetal endothelial cells: lack of mutations of exon 11 and exon 17 of c-kit. Mod Pathol 2000 13 : 536 41.
24. Komdeur R, Hoekstra HJ, Molenaar WM. Clinicopathologic assessment of post radiation sarcomas: kit as a potential treatment target. Clin Cancer Res 2003 9 : 2926 32.
25. McLean SR, Gana-Weisz M, Hartzoulakis B, et al. Imatinib binding and cKIT inhibition is abrogated by the cKIT kinase domain I missense mutation Val654Ala. Mol Cancer Ther 2005 4 : 2008 15.
26. Yamamato T, Umeda T, Nishioka K. Immunohistological distribution of stem cell factor and kit receptor in angiosarcoma. Acta Dermatol Venereol 2000 80 : 443 5.
27. Ma Y, Zeng S, Metcalfe D, et al. The c-kit mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002 99 : 1741 4.
28. von Mehren M, Watson JC. Gastrointestinal stromal tumors. Hematol Oncol Clin N Am 2005 19 : 547 64.
29. Liang WC, Wu X, Peale FV, et al. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 2006 281 : 951 61.
30. Koontz BF, Miles EF, Rubio MD, et al. Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies. Head Neck 2007 30 : 262 6.
31. Amo Y, Masuzawa M, Hamada Y, et al. Serum concentrations of vascular endothelial growth factor-D in angiosarcoma patients. Br J Dermatol 2004 150 : 160 1.